DISCLAIMER:
The author explicitly discourages any non-research handling of these substances due to their extreme potency and significant risk of fatal overdose.
The author does not condone, endorse, or encourage the use, production, or distribution of any substances mentioned herein, including but not limited to PHM (N-Phenethyl Noroxymorphone), MGM-15, O-DSMT, or morphine. All information is presented strictly for educational and harm-reduction knowledge within a research context.
This document does not constitute medical advice, dosing guidance, or a recommendation for any course of action. The potency equivalencies presented are theoretical and based on available pharmacological data; they do not reflect real-world safety, toxicity, or individual physiological responses. Any misuse of the information contained herein is solely the responsibility of the reader.
----------------------------------------------------------------------
1. SUBSTANCE IDENTITY & CHEMICAL INFORMATION
----------------------------------------------------------------------
Name: N-Phenethyl Noroxymorphone
Abbreviation: PHM
IUPAC Name: (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-phenylethyl)-
2,4,5,6,7a,13-hexahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7-one
Chemical Formula: C24H25NO4
Molecular Weight: 391.5 g/mol
Structural Analogies:
PHM is a derivative of the classic semi-synthetic opioid oxymorphone. The
defining structural modification is the substitution of the N-methyl group
of oxymorphone with a phenethyl group. This N-phenethyl substitution is
known to significantly alter pharmacological activity and increase potency.
PHM also shares structural similarities with naltrexone.
First Identification: The compound was first identified in drug material in
the United States (Pennsylvania) in October 2023, with subsequent detection
in Europe.
----------------------------------------------------------------------
2. PHARMACOKINETICS & PHARMACODYNAMICS
----------------------------------------------------------------------
Mode of Action:
PHM acts as a potent and highly selective agonist at the mu-opioid receptor
(MOR). It exhibits weak affinity for the kappa-opioid receptor.
Additionally, it has demonstrated potent activity as a TLR4 antagonist,
suggesting potential anti-inflammatory properties distinct from its opioid
effects.
Binding Affinity (Ki): 0.54 ± 0.03 nM (at MOR)
Functional Potency (EC50): 2.63 ± 1.06 nM (at MOR)
----------------------------------------------------------------------
3. POTENCY ANALYSIS (vs. MORPHINE)
----------------------------------------------------------------------
PHM is exceptionally potent. Its potency is estimated via two mechanisms:
1. Oxymorphone Baseline: Oxymorphone is approximately 10 times more potent
than morphine.
2. N-Phenethyl Effect: The N-phenethyl substitution in the morphinan
skeleton can produce up to a 12-fold increase in analgesic potency
compared to the parent molecule.
Potency Range:
Based on the above factors and provided research parameters, PHM is
estimated to be 100 times more potent than morphine (Morphine = 1.0).
In vitro studies specifically note that PHM has approximately twice the
affinity and potency of oxymorphone at the MOR.
----------------------------------------------------------------------
3. POTENTIAL HALF-LIFE (SPECULATIVE BASELINE)
----------------------------------------------------------------------
No empirical data regarding the human half-life of PHM (N-Phenethyl
Noroxymorphone) currently exists in the published literature.
Given the compound's structural identity as a direct analog of
oxymorphone—differing only by the substitution of the N-methyl
group with a phenethyl group—the most pharmacologically
relevant baseline for speculation is the established half-life
of oxymorphone itself. For immediate-release oxymorphone,
the elimination half-life is reported to be approximately 7–10 hours.
The N-phenethyl substitution, while significantly enhancing
mu-opioid receptor affinity and potency , may also alter
metabolic stability, protein binding, and lipophilicity,
potentially shifting the half-life in either direction.
Without formal studies, any estimate remains speculative.
However, for the purpose of preliminary risk assessment
and pharmacological comparison, a half-life roughly analogous
to that of oxymorphone—in the 9- to 11-hour range—serves
as the most reasonable working baseline until specific
data on PHM emerges.
Half-Life: After 6 Hours and still active, 9-10hours might be valid.
----------------------------------------------------------------------
5. COMPARATIVE POTENCY TABLES
----------------------------------------------------------------------
Table 1: Equivalency Doses (Reference: 5 mg PHM)
------------------------------------------------
| Substance | Potency Factor | Dose Equivalent |
| | (vs. Morphine) | to 5 mg PHM |
|-----------|----------------|-----------------|
| PHM | 100.0 | 5.0 mg |
| MGM-15 | 50.0 | 10.0 mg |
| Morphine | 1.0 | 500.0 mg |
| O-DSMT | 0.7 | 714.3 mg |
------------------------------------------------
Table 2: Potency Factors (Morphine = 1.0)
------------------------------------------------
| Substance | Potency Factor | Relative to Morphine |
|-----------|----------------|----------------------|
| O-DSMT | 0.7 | Less potent |
| Morphine | 1.0 | Baseline |
| MGM-15 | 50.0 | 50x more potent |
| PHM | 100.0 | 100x more potent |
------------------------------------------------
----------------------------------------------------------------------
6. RESEARCH CONTEXT & SAFETY NOTE
----------------------------------------------------------------------
The data presented here is for pharmacological comparison only. It does not
reflect safety profiles, therapeutic windows, or real-world risk
equivalencies. The equivalencies are theoretical and do not account for
differences in onset, duration, half-life, individual metabolism, or
Route of Administration (RoA) which significantly affect opioid effects
and toxicity.
The extreme potency of PHM and MGM-15 (50-100x morphine) classifies them
as high-risk NSOs. Doses in the milligram range produce effects equivalent
to hundreds of milligrams of morphine, indicating a severe risk of fatal
respiratory depression even at small measurement errors.
----------------------------------------------------------------------
7. EXPERIENCE REPORT
----------------------------------------------------------------------
Background: 40yrs, male, normal weight/fitness, lumbar disc herniation/ischialgia
- 20 years of direct experiential knowledge with psychoactive substances, with a specific focus on the opioid class
- pretty solid opioid tolerance, starting dose of 30mg MGM-15
- applied safer use guidelines (e.g. had a "trip sitter" to watch if i turn blue and pass out)
- back chasing the dragon: we should harvest the compound PHM as much and as long as we can - any ideas? DM ME!
0) Short allergy test
1) Sublingual 5mg PHM - 12:00
+ 20min: miosis, small itches, feeling of comfort, relatively low pain
+ 45min: NO f*cking PAIN, onset of slight euphoric feeling
+ 60min: light opioid buzz
+ 90min: bad night, so i lay down for a short nap
# of the course of the doses it has shown it's potential as µ agonist
2.) Sublingual 5mg PHM - 14:30
3.) Sublingual 5mg PHM - 15:00
4.) Sublingual 5mg PHM - 16:00
5.) Sublingual 5mg PHM - 17:00
6.) Sublingual 5mg PHM - 18:00
Summary: Profile of a µ agonist, about as twice as strong as MGM-15. speaking of euphoria and other side effects (respiratory depression, miosis, itchying) i does not hide behind oxy, mgm or other potent agonists.
I will update next week after a longer time and more detailed test with higher initial doses.
The author explicitly discourages any non-research handling of these substances due to their extreme potency and significant risk of fatal overdose.
The author does not condone, endorse, or encourage the use, production, or distribution of any substances mentioned herein, including but not limited to PHM (N-Phenethyl Noroxymorphone), MGM-15, O-DSMT, or morphine. All information is presented strictly for educational and harm-reduction knowledge within a research context.
This document does not constitute medical advice, dosing guidance, or a recommendation for any course of action. The potency equivalencies presented are theoretical and based on available pharmacological data; they do not reflect real-world safety, toxicity, or individual physiological responses. Any misuse of the information contained herein is solely the responsibility of the reader.
----------------------------------------------------------------------
1. SUBSTANCE IDENTITY & CHEMICAL INFORMATION
----------------------------------------------------------------------
Name: N-Phenethyl Noroxymorphone
Abbreviation: PHM
IUPAC Name: (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-phenylethyl)-
2,4,5,6,7a,13-hexahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7-one
Chemical Formula: C24H25NO4
Molecular Weight: 391.5 g/mol
Structural Analogies:
PHM is a derivative of the classic semi-synthetic opioid oxymorphone. The
defining structural modification is the substitution of the N-methyl group
of oxymorphone with a phenethyl group. This N-phenethyl substitution is
known to significantly alter pharmacological activity and increase potency.
PHM also shares structural similarities with naltrexone.
First Identification: The compound was first identified in drug material in
the United States (Pennsylvania) in October 2023, with subsequent detection
in Europe.
----------------------------------------------------------------------
2. PHARMACOKINETICS & PHARMACODYNAMICS
----------------------------------------------------------------------
Mode of Action:
PHM acts as a potent and highly selective agonist at the mu-opioid receptor
(MOR). It exhibits weak affinity for the kappa-opioid receptor.
Additionally, it has demonstrated potent activity as a TLR4 antagonist,
suggesting potential anti-inflammatory properties distinct from its opioid
effects.
Binding Affinity (Ki): 0.54 ± 0.03 nM (at MOR)
Functional Potency (EC50): 2.63 ± 1.06 nM (at MOR)
----------------------------------------------------------------------
3. POTENCY ANALYSIS (vs. MORPHINE)
----------------------------------------------------------------------
PHM is exceptionally potent. Its potency is estimated via two mechanisms:
1. Oxymorphone Baseline: Oxymorphone is approximately 10 times more potent
than morphine.
2. N-Phenethyl Effect: The N-phenethyl substitution in the morphinan
skeleton can produce up to a 12-fold increase in analgesic potency
compared to the parent molecule.
Potency Range:
Based on the above factors and provided research parameters, PHM is
estimated to be 100 times more potent than morphine (Morphine = 1.0).
In vitro studies specifically note that PHM has approximately twice the
affinity and potency of oxymorphone at the MOR.
----------------------------------------------------------------------
3. POTENTIAL HALF-LIFE (SPECULATIVE BASELINE)
----------------------------------------------------------------------
No empirical data regarding the human half-life of PHM (N-Phenethyl
Noroxymorphone) currently exists in the published literature.
Given the compound's structural identity as a direct analog of
oxymorphone—differing only by the substitution of the N-methyl
group with a phenethyl group—the most pharmacologically
relevant baseline for speculation is the established half-life
of oxymorphone itself. For immediate-release oxymorphone,
the elimination half-life is reported to be approximately 7–10 hours.
The N-phenethyl substitution, while significantly enhancing
mu-opioid receptor affinity and potency , may also alter
metabolic stability, protein binding, and lipophilicity,
potentially shifting the half-life in either direction.
Without formal studies, any estimate remains speculative.
However, for the purpose of preliminary risk assessment
and pharmacological comparison, a half-life roughly analogous
to that of oxymorphone—in the 9- to 11-hour range—serves
as the most reasonable working baseline until specific
data on PHM emerges.
Half-Life: After 6 Hours and still active, 9-10hours might be valid.
----------------------------------------------------------------------
5. COMPARATIVE POTENCY TABLES
----------------------------------------------------------------------
Table 1: Equivalency Doses (Reference: 5 mg PHM)
------------------------------------------------
| Substance | Potency Factor | Dose Equivalent |
| | (vs. Morphine) | to 5 mg PHM |
|-----------|----------------|-----------------|
| PHM | 100.0 | 5.0 mg |
| MGM-15 | 50.0 | 10.0 mg |
| Morphine | 1.0 | 500.0 mg |
| O-DSMT | 0.7 | 714.3 mg |
------------------------------------------------
Table 2: Potency Factors (Morphine = 1.0)
------------------------------------------------
| Substance | Potency Factor | Relative to Morphine |
|-----------|----------------|----------------------|
| O-DSMT | 0.7 | Less potent |
| Morphine | 1.0 | Baseline |
| MGM-15 | 50.0 | 50x more potent |
| PHM | 100.0 | 100x more potent |
------------------------------------------------
----------------------------------------------------------------------
6. RESEARCH CONTEXT & SAFETY NOTE
----------------------------------------------------------------------
The data presented here is for pharmacological comparison only. It does not
reflect safety profiles, therapeutic windows, or real-world risk
equivalencies. The equivalencies are theoretical and do not account for
differences in onset, duration, half-life, individual metabolism, or
Route of Administration (RoA) which significantly affect opioid effects
and toxicity.
The extreme potency of PHM and MGM-15 (50-100x morphine) classifies them
as high-risk NSOs. Doses in the milligram range produce effects equivalent
to hundreds of milligrams of morphine, indicating a severe risk of fatal
respiratory depression even at small measurement errors.
----------------------------------------------------------------------
7. EXPERIENCE REPORT
----------------------------------------------------------------------
Background: 40yrs, male, normal weight/fitness, lumbar disc herniation/ischialgia
- 20 years of direct experiential knowledge with psychoactive substances, with a specific focus on the opioid class
- pretty solid opioid tolerance, starting dose of 30mg MGM-15
- applied safer use guidelines (e.g. had a "trip sitter" to watch if i turn blue and pass out)
- back chasing the dragon: we should harvest the compound PHM as much and as long as we can - any ideas? DM ME!
0) Short allergy test
1) Sublingual 5mg PHM - 12:00
+ 20min: miosis, small itches, feeling of comfort, relatively low pain
+ 45min: NO f*cking PAIN, onset of slight euphoric feeling
+ 60min: light opioid buzz
+ 90min: bad night, so i lay down for a short nap
# of the course of the doses it has shown it's potential as µ agonist
2.) Sublingual 5mg PHM - 14:30
3.) Sublingual 5mg PHM - 15:00
4.) Sublingual 5mg PHM - 16:00
5.) Sublingual 5mg PHM - 17:00
6.) Sublingual 5mg PHM - 18:00
Summary: Profile of a µ agonist, about as twice as strong as MGM-15. speaking of euphoria and other side effects (respiratory depression, miosis, itchying) i does not hide behind oxy, mgm or other potent agonists.
I will update next week after a longer time and more detailed test with higher initial doses.
Last edited:
